Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes

INTRODUCTION: Inflammatory bowel disease (IBD) consisting of Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory conditions affecting the gastrointestinal tract. Infliximab (IFX) is a chimeric anti‐tumor necrosis factor antibody used to treat moderate to severe IBD. Eosinophils ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zabrowski, Douglas, Abraham, Danielle, Rosenthal, Geoffrey, Kader, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411706/
https://www.ncbi.nlm.nih.gov/pubmed/32782950
http://dx.doi.org/10.1002/jgh3.12308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411706/
https://www.ncbi.nlm.nih.gov/pubmed/32782950
http://dx.doi.org/10.1002/jgh3.12308

Ejemplares similares